Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022047128 - METHOD FOR TREATING COMPLEMENT MEDIATED DISORDERS CAUSED BY BETACORONAVIRUSES

Publication Number WO/2022/047128
Publication Date 03.03.2022
International Application No. PCT/US2021/047901
International Filing Date 27.08.2021
IPC
A61K 31/416 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
A61K 31/505 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K 31/44 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
C07D 207/02 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
G01N 2333/165
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
G01N 2333/4716
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
Applicants
  • ALEXION PHARMACEUTICALS, INC. [US]/[US]
  • THE JOHNS HOPKINS UNIVERSITY [US]/[US]
Inventors
  • VARDI, Moshe
  • BRODSKY, Robert, A.
  • GAO, Xiang
  • KAZANI, Shamsah, D.
  • NAGALI, Venu
  • YUAN, Xuan
Agents
  • ELLISON, Jeffrey, J.
Priority Data
63/071,54728.08.2020US
63/159,08910.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR TREATING COMPLEMENT MEDIATED DISORDERS CAUSED BY BETACORONAVIRUSES
(FR) PROCÉDÉ DE TRAITEMENT DE TROUBLES MÉDIÉS PAR LE COMPLÉMENT PROVOQUÉS PAR DES BÉTACORONAVIRUS
Abstract
(EN) The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by a betacoronavirus, e.g., SARS-CoV, MERS-CoV, or SARS-CoV-2, in a human subject. The methods of treatment include administering to the human subject a therapeutically effective amount of at least one complement factor D inhibitor. Also provided herein are compounds for treating an infection by a betacoronavirus and their use in the manufacture in a medicament for treating an infection by a betacoronavirus.
(FR) La présente invention concerne des procédés et des compositions utiles pour le diagnostic et le traitement d'une voie alternative activée du complément chez un sujet humain atteint d'une infection par le SARS-CoV -2. L'invention concerne également des procédés de traitement d'une infection par un bétacoronavirus, par exemple le SARS-CoV, le MERS-CoV, ou le SARS-CoV-2, chez un sujet humain. Les procédés de traitement comprennent l'administration au sujet humain d'une quantité thérapeutiquement efficace d'au moins un inhibiteur du facteur D du complément. L'invention concerne également des composés pour le traitement d'une infection par un bétacoronavirus et leur utilisation dans la fabrication d'un médicament pour le traitement d'une infection par un bétacoronavirus.
Latest bibliographic data on file with the International Bureau